The Increasing Prevalence of Gout in the World Is Driving Gout Disease Treatment Market Growth

Gout Disease Treatment Market

Gout Disease Treatment Market, by Drug Class (Nonsteroidal Anti-inflammatory Drugs (NSAIDs), Corticosteroids, Colchicine, Urate-lowering Agents, and Monoclonal Antibody), by Route of Administration (Oral and Injectable), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2019 - 2027.

Market Overview:

Gout is a type of arthritis that occurs when uric acid builds up in the blood and forms crystals in the joints. This can cause sudden and severe pain, swelling, and redness in the affected joint. Gout typically affects the big toe, but can also occur in other joints such as the ankle, knee, wrist, and elbow. Gout is a chronic condition that can lead to joint damage and other complications if left untreated. It is often treated with medication and lifestyle changes, such as a low-purine diet and weight loss. Gout is more common in men than in women and is often associated with other health conditions such as high blood pressure, diabetes, and kidney disease.

Competitive Landscape:

Major players operating in the global gout disease treatment market include Zyla Life Sciences (Pty) Ltd., CymaBay Therapeutics, Inc., Ironwood Pharmaceuticals, Inc., Hikma Pharmaceuticals Plc, Horizon Therapeutics Plc., JW Pharmaceutical Corporation, Simcere Pharmaceutical, Teijin Pharma Limited, Novartis International AG, Takeda Pharmaceutical Company Limited, and AstraZeneca Plc.

Key Market Drivers:

The increasing prevalence of gout disease in the world is expected to augment the growth of the global gout disease treatment market. For instance, according to the National Institutes of Health (NIH), globally around 7.44 million individuals are living with gout disease. For instance, according to the National Institutes of Health (NIH), globally around 7.44 million individuals are living with gout disease.

The growing awareness about gout and its symptoms and the development of new drugs and treatment options in the world are estimated to enhance the growth of the global gout disease treatment market.

Covid-19 Impact Analysis:

The COVID-19 pandemic has had a mixed impact on the gout disease treatment market. While the pandemic has led to a decline in hospital visits, which has affected the diagnosis and treatment of gout patients, the increasing adoption of telemedicine and online consultations has helped maintain the continuity of care for patients. Additionally, the demand for gout treatment has remained stable, with patients continuing to require treatment despite the pandemic. For instance, in March 2022, Atom Bioscience published the positive results of the clinical trial related to ABP-671, which will be used to treat chronic gout disease.

Key Takeaways:

·         North America is expected to dominate the growth of the global gout disease treatment market, owing to the high prevalence of gout and the presence of major market players in the region. For instance, according to JAMA Network, around 9.2 million individuals in the United States are suffering from gout disease.

·         Asia-Pacific is estimated to witness significant growth in the global gout disease treatment market, owing to the increasing prevalence of gout and rising healthcare expenditure in the region. For instance, in March 2022, Stride Pharma got the approval of the United States Food and Drug Administration, for its Colchicine tablets, which will be used to prevent and treat gout disease.